OCM
NVCT icon

Occam Crest Management’s Nuvectis Pharma NVCT Stock Holding History

Occam Crest Management’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.16M Buy
+4,800
New +$53.7K 2.68% 15

Other funds holding NVCT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IAM
Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Occam Crest Management's NVCT Position: Q2 2026 in Review

Occam Crest Management reduced its Nuvectis Pharma (NVCT) stake by 12% in Q2 2026, selling an estimated $560K and leaving 357,147 shares worth $7.39M. The position accounts for 3.84% of the portfolio, ranked #9.

Occam Crest Management first reported a position in NVCT in Q3 2025 and has held it in 4 quarters since. 83 funds tracked by Wall St. Rank hold NVCT as of Q2 2026.

  • Occam Crest Management held 357,147 shares of Nuvectis Pharma worth $7.39M as of Q2 2026.
  • Occam Crest Management sold 50,000 Nuvectis Pharma shares in Q2 2026, an estimated $560K.
  • Nuvectis Pharma made up 3.84% of Occam Crest Management's portfolio in Q2 2026, its #9 holding.
  • Occam Crest Management first reported a position in Nuvectis Pharma in Q3 2025 and has held it in 4 quarters since.
  • 83 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q2 2026.

Based on Occam Crest Management's 13F filing for Q2 2026, filed 14 Aug 2026.